The association between metabolic syndrome and vascular endothelial dysfunction in adolescents

Experimental and Therapeutic Medicine

Volumn 5, Issue 6, 2013, Pages 1663-1666

  Wei, Ying ^a   Liu, Geli ^a   Yang, Jingyan ^a   Zheng, Rongxiu ^a   Jiang, Lihong ^a   Bao, Pengli ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Metabolic syndrome; Plasminogen activator inhibitor 1; Vascular endothelium functional lesion; Von Willebrand factor

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADOLESCENT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIP CIRCUMFERENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCHOOL CHILD; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

EID: 84876548971     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1055     Document Type: Article

References (26)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486-2497, 2001.
2. Lim HS, Lip GY and Blann AD: Plasma von Willebrand factor and the development of the metabolic syndrome in patients with hypertension. J Clin Endocrinol Metab 89: 5377-5381, 2004.
3. Blann AD, Naqvi T, Waite M and McCollum CN: von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens 7: 107-111, 1993.
4. Felmeden DC, Spencer CG, Belgore FM, Blann AD, Beevers DG and Lip GY: Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 16: 11-20, 2003.
5. Thompson SG, Kienast J, Pyke SD, Haverkate F and van de Loo JC; European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332: 635-641, 1995
6. Meigs JB, Mittleman MA, Nathan DM, et al: Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 283: 221-228, 2000.
7. Alessi MC and Juhan-Vague I: PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 26: 2200-2207, 2006.
8. Pi-Sunyer FX: Obesity: criteria and classification. Proc Nutr Soc 59: 505-509, 2000.
9. Zimmet P, Alberti G, Kaufman F, et al: The metabolic syndrome in children and adolescents. Lancet 369: 2059-2061, 2007.
10. Alberti KG and Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553, 1998.
11. Cook S, Weitzman M, Auinger P, Nguyen M and Dietz WH: Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 157: 821-827, 2003.
12. Steinberger J and Daniels SR: Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 107: 1448-1453, 2003.
13. Hanson M and Gluckman P: Endothelial dysfunction and cardiovascular disease: the role of predictive adaptive responses. Heart 91: 864-866, 2005.
14. Versari D, Daghini E, Virdis A, Ghiadoni L and Taddei S: Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 32 (Suppl 2): S314-S321, 2009.
15. Bell DM, Johns TE and Lopez LM: Endothelial dysfunction: implications for therapy of cardiovascular diseases. Ann Pharmacother 32: 459-470, 1998.
16. Dusheiko GM: Review article: the management of hepatitis A, B, D and non-A non-B. Aliment Pharmacol Ther 3: 1-20, 1989.
17. Binder BR, Christ G, Gruber F, et al: Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 17: 56-61, 2002.
18. Huang K, Zou CC, Yang XZ, et al: Carotid intima-media thickness and serum endothelial marker levels in obese children with metabolic syndrome. Arch Pediatr Adolesc Med 164: 846-851, 2010.
19. Carr DB, Utzschneider KM, Hull RL, et al: Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53: 2087-2094, 2004.
20. Aggoun Y: Obesity, metabolic syndrome, and cardiovascular disease. Pediatr Res 61: 653-659, 2007.
21. Nesto RW: The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med 4 (Suppl 6): S11-S18, 2003.
22. Chong AY, Blann AD and Lip GY: Assessment of endothelial damage and dysfunction: observations in relation to heart failure. QJM 96: 253-267, 2003.
23. Pinkney JH, Stehouwer CD, Coppack SW and Yudkin JS: Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 46 (Suppl 2): S9-S13, 1997.
24. Conlan MG, Folsom AR, Finch A, et al: Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 70: 380-385, 1993.
25. Wen Y, Gu J, Li SL, et al: Elevated glucose and diabetes promote interleukin-12 cytokine gene expression in mouse macrophages. Endocrinology 147: 2518-2525, 2006.
26. Myers JE and Baker PN: Hypertensive diseases and eclampsia. Curr Opin Obstet Gynecol 14: 119-125, 2002.